A retrospective study reported that the duration of PD1/PD-L1 inhibitors could be amplified by local therapy, such as radiotherapy, to solitary or oligo-progressive sites in atypical response, especially among those harboring a biologically more indolent cancer type, such as renal cancer [24]. Here, CD274 is linked to renal carcinoma.